Doctors can prescribe Mounjaro off-label for weight loss, but the drug does not have FDA approval for this use. Tirzepatide is FDA-approved for weight loss as the brand-name drug Zepbound.

It turns out that the anti-obesity space isn't growing as fast as Eli Lilly or analysts anticipated, resulting in ...

Your doctor may also prescribe Mounjaro off-label for weight management ... (An active ingredient is what makes a drug work.) Another drug, Zepbound, also contains the same active ingredient ...

With off-label use, doctors prescribe a drug for ... For a cost comparison of Ozempic versus Wegovy or Mounjaro versus Zepbound, talk with your doctor or insurance provider. You can also check ...

The shortage, which began in December 2022 for Mounjaro and extended to Zepbound in April 2023, led to a surge in demand for compounded versions of the drugs. But with tirzepatide removed from the ...

Shares of Eli Lilly & Co. were headed for their worst day in nearly four years on Tuesday after the drugmaker provided a fourth-quarter revenue outlook that was below expectations, citing slower ...

Why it matters: Lilly's growth prospects are driven by Mounjaro and Zepbound, and shortfalls in sales could portend weaker long-term potential for this market. Lilly is positioned to remain the ...

Once again, the drugmaker reported sales of its blockbuster GLP-1 medicines Zepbound and Mounjaro that missed Wall Street estimates. It was the second consecutive miss for the two closely watched ...

Also, Lilly looks well placed to get approval for several new drugs and label expansions for marketed drugs, including Mounjaro and Zepbound, in the next few years. The board of directors of Lilly ...

We could point out that tirzepatide, the active ingredient in Mounjaro and Zepbound, is still undergoing many clinical trials and should earn key label expansions. Last year, the medicine aced a ...